

Zimu Gong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7394228/publications.pdf>

Version: 2024-02-01

33
papers

409
citations

1163117

8
h-index

940533

16
g-index

34
all docs

34
docs citations

34
times ranked

586
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study. , 2018, 6, 142.		146
2	Immune Checkpoint Inhibitor–Mediated Diarrhea and Colitis: A Clinical Review. JCO Oncology Practice, 2020, 16, 453-461.	2.9	42
3	Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer Journal, 2017, 7, e583-e583.	6.2	40
4	Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. Blood Advances, 2017, 1, 2541-2552.	5.2	37
5	Stent implantation in patients with metal allergy. Coronary Artery Disease, 2013, 24, 684-689.	0.7	23
6	Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. Modern Pathology, 2018, 31, 1141-1154.	5.5	23
7	Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value. Cancer, 2018, 124, 3849-3855.	4.1	18
8	Comparison of treatment modalities in pancreatic pseudocyst: A population based study. World Journal of Gastrointestinal Surgery, 2019, 11, 365-372.	1.5	13
9	Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia. Blood Cancer Journal, 2017, 7, e521-e521.	6.2	9
10	Extranodal nasal-type natural killer/T-cell lymphoma with penile involvement: a case report and review of the literature. BMC Urology, 2017, 17, 77.	1.4	9
11	The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma. Modern Pathology, 2021, 34, 327-335.	5.5	7
12	Outcomes of Immune Checkpoint Inhibitor–related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 402-408.	1.3	7
13	Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Annals of Hematology, 2017, 96, 501-504.	1.8	6
14	Factor Xa inhibitors versus low molecular weight heparin for the treatment of cancer associated venous thromboembolism; A meta-analysis of randomized controlled trials and non-randomized studies. Critical Reviews in Oncology/Hematology, 2022, 169, 103526.	4.4	6
15	Philadelphia chromosome–negative acute leukemia in patients with chronic myeloid leukemia. American Journal of Hematology, 2019, 94, E256-E259.	4.1	4
16	Gastrointestinal, pancreatic, and hepatic toxicity profile of CTLA-4 immune checkpoint inhibitors alone and in combination with PD-1/PD-L1 inhibitors: A meta-analysis of clinical trials.. Journal of Clinical Oncology, 2019, 37, e14117-e14117.	1.6	4
17	T–lymphoid or T/myeloid blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy: a report of 14 cases. International Journal of Laboratory Hematology, 2017, 39, e45-e50.	1.3	2
18	Mixed Phenotype Blast Phase of Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitor Therapy. Blood, 2016, 128, 5438-5438.	1.4	2

#	ARTICLE	IF	CITATIONS
19	A Limited-Versus-Extensive Staging Strategy for Small Cell Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 87-93.	1.3	1
20	Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia. British Journal of Haematology, 2020, 189, e207-e211.	2.5	1
21	Outcomes of Vedolizumab Treatment in Patients With Immune Checkpoint Inhibitor-Induced Diarrhea and Colitis: A Multi-Center Study. American Journal of Gastroenterology, 2018, 113, S58.	0.4	1
22	Cytogenetic alterations in CML: not all created equal. Oncotarget, 2018, 9, 11885-11886.	1.8	1
23	Revolutionary changes in salvage treatment for Hodgkin lymphoma: toward a chemotherapy-free future. Annals of Translational Medicine, 2018, 6, 237-237.	1.7	1
24	Prognostic impact of hepatic involvement on spontaneous tumor lysis syndrome in solid tumors.. Journal of Clinical Oncology, 2020, 38, e19098-e19098.	1.6	1
25	PROGNOSTIC IMPACT OF ATRIAL FIBRILLATION ON ACUTE ISCHEMIC STROKE PATIENTS TREATED WITH THROMBOLYSIS. Journal of the American College of Cardiology, 2020, 75, 470.	2.8	0
26	Impact of pretreatment serum creatinine on outcomes in pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, e15749-e15749.	1.6	0
27	Inpatient outcome of solid tumor associated tumor lysis syndrome.. Journal of Clinical Oncology, 2019, 37, e18185-e18185.	1.6	0
28	The safety and tolerability of PD-1/PDL-1 inhibitors in hematologic malignancies: A meta-analysis.. Journal of Clinical Oncology, 2019, 37, e14131-e14131.	1.6	0
29	Abstract 4189: Limited-versus-extensive staging system for small cell prostate cancer. , 2019, , .		0
30	Trends, Predictors and Outcomes of Portal Vein Thrombosis in Hospitalized Pancreatic Cancer Patients: National Inpatient Sample Analysis 1998-2016. Blood, 2019, 134, 4949-4949.	1.4	0
31	Impact of Asthma on Inpatient Outcome of Sickle Cell Crisis: A Population-Based Study. Blood, 2019, 134, 4842-4842.	1.4	0
32	Trends and Outcomes of Venous Thromboembolism in Hospitalized Patients with Pancreatic Cancer: Results from National Inpatient Sample Database 1998-2016. Blood, 2019, 134, 4953-4953.	1.4	0
33	Abstract 4189: Limited-versus-extensive staging system for small cell prostate cancer. , 2019, , .		0